Estelle® Phase IIB Results on Well-Being and Body Weight Published in Leading Peer-Reviewed journal

  • European Journal Of Contraception and Reproductive Health Care publishes article on Phase IIb results of Estelle®, Mithra’s combined oral contraceptive candidate
  • Article reports on Estelle’s® high acceptability, user satisfaction and general well-being in addition to favorable body weight control
  • Estelle® is currently being tested in two large-scale Phase III studies, with top-line results expected in Q3 2018-Q1 2019

Liège, Belgium, 26 June 2017 – Mithra (Euronext Brussels: MITRA), a company specialized in Women’s Health, announces that the European Journal of Contraception and Reproductive Health Care, one of the most prestigious peer-reviewed journals in the field, has published an article[1] detailing the acceptability, user satisfaction, well-being and body weight control of Estelle® in the Phase IIb FIESTA study. Estelle® is Mithra’s combined oral contraceptive (COC) candidate, composed of 15 mg Estetrol (E4) and 3 mg drospirenone (DRSP). Estelle® is currently being tested in two Phase III trials in Europe/Russia and in the US/Canada, the results of which should be available in Q3 2018 and Q1 2019, respectively.

[1] Article available online at http://www.tandfonline.com/doi/full/10.1080/13625187.2017.1336532